The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

An imbalance in a person’s glutamate levels can lead to exhaustion, concentration issues, and clinical depressive problems. The FDA fast-tracked Spravato’s approval through its Priority Review ...

Esketamine has been shown to affect glutamate signaling in a matter of days, while oral antidepressants can take weeks. Spravato isn’t like the nasal spray you use when you have a cold.

Spravato targets glutamate in the brain, which is the most abundant excitatory neurotransmitter. Since there are some side effects, including sedation, respiratory depression and misuse ...

Spravato targets the neurotransmitter glutamate; however, the mechanism by which esketamine exerts its antidepressant effect is unknown. In an effort to ensure the safe and appropriate use of ...

At least 21 million adults in the U.S. have experienced depression. And, while oral antidepressant medications are a common treatment, they don't work for everyone. Now, the Food and Drug ...

SPRAVATO ® is unique and works by targeting glutamate, which is the most abundant excitatory neurotransmitter in the brain. 6 The mechanism by which esketamine exerts its antidepressant effect is ...

What makes it different is how it works – it targets glutamate, a neurotransmitter that helps brain cells communicate. Clinical trials have shown impressive results. Spravato can start improving ...